397 related articles for article (PubMed ID: 33096269)
21. Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Oliveira G; Egloff AM; Afeyan AB; Wolff JO; Zeng Z; Chernock RD; Zhou L; Messier C; Lizotte P; Pfaff KL; Stromhaug K; Penter L; Haddad RI; Hanna GJ; Schoenfeld JD; Goguen LA; Annino DJ; Jo V; Oppelt P; Pipkorn P; Jackson R; Puram SV; Paniello RC; Rich JT; Webb J; Zevallos JP; Mansour M; Fu J; Dunn GP; Rodig SJ; Ley J; Morris LGT; Dunn L; Paweletz CP; Kallogjeri D; Piccirillo JF; Adkins DR; Wu CJ; Uppaluri R
Sci Immunol; 2023 Sep; 8(87):eadf4968. PubMed ID: 37683037
[TBL] [Abstract][Full Text] [Related]
22. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
[TBL] [Abstract][Full Text] [Related]
23. NFATc1 Promotes Antitumoral Effector Functions and Memory CD8
Heim L; Friedrich J; Engelhardt M; Trufa DI; Geppert CI; Rieker RJ; Sirbu H; Finotto S
Cancer Res; 2018 Jul; 78(13):3619-3633. PubMed ID: 29691251
[TBL] [Abstract][Full Text] [Related]
24. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
25. Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy.
Zhang C; Yin K; Liu SY; Yan LX; Su J; Wu YL; Zhang XC; Zhong WZ; Yang XN
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820821
[TBL] [Abstract][Full Text] [Related]
26. Dynamic changes in circulating PD-1
Kim CG; Hong MH; Kim KH; Seo IH; Ahn BC; Pyo KH; Synn CB; Yoon HI; Shim HS; Lee YI; Choi SJ; Lee YJ; Kim EJ; Kim Y; Kwak JE; Jung J; Park SH; Paik S; Shin EC; Kim HR
Eur J Cancer; 2021 Jan; 143():113-126. PubMed ID: 33302114
[TBL] [Abstract][Full Text] [Related]
27. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.
Luoma AM; Suo S; Wang Y; Gunasti L; Porter CBM; Nabilsi N; Tadros J; Ferretti AP; Liao S; Gurer C; Chen YH; Criscitiello S; Ricker CA; Dionne D; Rozenblatt-Rosen O; Uppaluri R; Haddad RI; Ashenberg O; Regev A; Van Allen EM; MacBeath G; Schoenfeld JD; Wucherpfennig KW
Cell; 2022 Aug; 185(16):2918-2935.e29. PubMed ID: 35803260
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
29. CD8
Huang B; Liu R; Wang P; Yuan Z; Yang J; Xiong H; Zhang N; Huang Q; Fu X; Sun W; Li L
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32606053
[TBL] [Abstract][Full Text] [Related]
30. Analysis of Immune Landscape Reveals Prognostic Significance of Cytotoxic CD4
Qi J; Liu X; Yan P; He S; Lin Y; Huang Z; Zhang S; Xie S; Li Y; Lu X; Wu Y; Zhou Y; Yuan J; Cai T; Zheng X; Ding Y; Yang W
Front Oncol; 2021; 11():724232. PubMed ID: 34631551
[TBL] [Abstract][Full Text] [Related]
31. The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis.
Bozcuk H; Abali H; Coskun S;
World J Surg Oncol; 2012 Aug; 10(1):161. PubMed ID: 22877422
[TBL] [Abstract][Full Text] [Related]
32. Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade.
Banchereau R; Chitre AS; Scherl A; Wu TD; Patil NS; de Almeida P; Kadel Iii EE; Madireddi S; Au-Yeung A; Takahashi C; Chen YJ; Modrusan Z; McBride J; Nersesian R; El-Gabry EA; Robida MD; Hung JC; Kowanetz M; Zou W; McCleland M; Caplazi P; Eshgi ST; Koeppen H; Hegde PS; Mellman I; Mathews WR; Powles T; Mariathasan S; Grogan J; O'Gorman WE
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827905
[TBL] [Abstract][Full Text] [Related]
33. Resident memory T cells, critical components in tumor immunology.
Mami-Chouaib F; Blanc C; Corgnac S; Hans S; Malenica I; Granier C; Tihy I; Tartour E
J Immunother Cancer; 2018 Sep; 6(1):87. PubMed ID: 30180905
[TBL] [Abstract][Full Text] [Related]
34. The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.
Lonie JM; Brosda S; Bonazzi VF; Aoude LG; Patel K; Brown I; Sharma S; Lampe G; Addala V; Koufariotis LT; Wood S; Waddell N; Dolcetti R; Barbour AP
Front Immunol; 2023; 14():1220129. PubMed ID: 37965317
[TBL] [Abstract][Full Text] [Related]
35. Single-cell transcriptomics reveals tumor-infiltrating B cell function after neoadjuvant pembrolizumab and chemotherapy in non-small cell lung cancer.
Hou L; Zhang S; Yu W; Yang X; Shen M; Hao X; Ren X; Sun Q
J Leukoc Biol; 2023 Nov; ():. PubMed ID: 37931147
[TBL] [Abstract][Full Text] [Related]
36. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients.
de Goeje PL; Poncin M; Bezemer K; Kaijen-Lambers MEH; Groen HJM; Smit EF; Dingemans AC; Kunert A; Hendriks RW; Aerts JGJV
Clin Cancer Res; 2019 Apr; 25(7):2219-2227. PubMed ID: 30642911
[TBL] [Abstract][Full Text] [Related]
37. Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC).
Hui Z; Zhang J; Ren Y; Li X; Yan C; Yu W; Wang T; Xiao S; Chen Y; Zhang R; Wei F; You J; Ren X
Cell Death Dis; 2022 Jul; 13(7):607. PubMed ID: 35831283
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
Friedman J; Moore EC; Zolkind P; Robbins Y; Clavijo PE; Sun L; Greene S; Morisada MV; Mydlarz WK; Schmitt N; Hodge JW; Schreiber H; Van Waes C; Uppaluri R; Allen C
Clin Cancer Res; 2020 Feb; 26(3):679-689. PubMed ID: 31645352
[TBL] [Abstract][Full Text] [Related]
39. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
40. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
